Peritoneal carcinomatosis in patients with digestive endocrine tumors

Vasseur, B.; Cadiot, G.; Zins, Marc; Fléjou, J.-F.; Belghiti, J.; Jp, Marmuse; Vilgrain, Valérie; Bernadès, P; Mignon, M; Ruszniewski, Philippe

doi:10.1002/(sici)1097-0142(19961015)78:8<1686::aid-cncr8>3.3.co;2-s

Cited by 5 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse mesenteric/peritoneal disease, with peritoneal studding or ascites, is seen in 20%–30% of patients with a GI carcinoid and may be associated with obstruction [68, 78]. Peritoneal disease is less common in pancreatic endocrine tumours; it was seen in 11% of non-gastrinoma pancreatic endocrine tumours but did not occur in association with a gastrinoma in one series [78].…”

Section: Metastases From Pancreatic and Carcinoid Neuroendocrine Tumoursmentioning

confidence: 99%

See 1 more Smart Citation

CT/MRI of neuroendocrine tumours

Reznek

2006

Cancer Imaging

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are often thought to be rare and rather recherché cancers which are of little concern to the general physician, surgeon or radiologist because of their rarity and esoteric nature. In fact, while relatively uncommon, the total group of gastro-entero-pancreatic (GEP) tumours incorporates the spectrum of all types of carcinoids, incuding bronchial carcinoids, and the whole gamut of islet-cell tumours. Some of these may present as functioning tumours, with a plethora of hormonal secretions and concomitant clinical syndromes, and GEPs in general have an incidence around 30 per million population per year. This means that in the whole European Union, for example, there will be in the region of 12 000 new patients every year presenting with one or another manifestation of these tumours. Furthermore, the comparatively long survival of many of these patients, compared to more common adenocarcinomas or epithelial tumours, implies that the point prevalence is also not inconsiderable. However, it is undoubtedly true that these tumours can be difficult to identify, especially in their early stages, and it is then that radiological investigation becomes of paramount importance. Having taken into account all these considerations, most investigators would initiate investigation of a suspected or biochemically proven islet-cell tumour with cross-sectional imaging-either CT or MRI. This will clearly identify the larger lesions, allow assessment of the entire abdomen, and provide valuable information on the presence of hepatic metastates.

show abstract

Section: Metastases From Pancreatic and Carcinoid Neuroendocrine Tumoursmentioning

confidence: 99%

“…Peritoneal disease is less common in pancreatic endocrine tumours; it was seen in 11% of non-gastrinoma pancreatic endocrine tumours but did not occur in association with a gastrinoma in one series [78]. …”

Section: Metastases From Pancreatic and Carcinoid Neuroendocrine Tumoursmentioning

confidence: 99%

CT/MRI of neuroendocrine tumours

Reznek

2006

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…3 In their earlier review of 116 patients with digestive endocrine tumors, Vasseur et al did not identify any patients with appendiceal primaries, 11 of whom had peritoneal carcinomatosis. 4 More recent case studies applying modern histological classification criteria include that of Kleiman et al, which did not identify any incidence of peritoneal dissemination in their 78 patients. 5 We recently reported the largest non-registry surgical cohort of 215 patients with ANET treated at three tertiary referral centers, and while we documented a rate of lymph node metastases of 7.9% at the index appendectomy and 24.5% at the completion hemicolectomy, only two patients (\1%) had liver metastases and none had evidence of PM.…”

mentioning

confidence: 99%

Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors

Frilling

Clift

2017

Ann Surg Oncol

View full text Add to dashboard Cite

“…Peritoneal metastasis from neuroendocrine tumors (NET) is not uncommon with a range in incidence from 10% to 33% . Carcinomatosis can be asymptomatic with incidental discovery during preoperative imaging or resection of the primary tumor, but may also occasionally cause significant morbidity with bowel obstruction and bleeding.…”

mentioning

confidence: 99%

“…The frequent association of peritoneal and liver metastases makes the management of patients with NET more complicated . While Vasseur et al did not find any change in survival due to carcinomatosis per se from NET, Elias et al found that peritoneal carcinomatosis was the direct cause of death in 40% patients with NET if left untreated .…”

mentioning

confidence: 99%